Replimune Group, Inc. (REPL) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Replimune Group, Inc. (REPL) stock forecast summary
Our AI ranks Replimune Group, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Replimune Group, Inc. is a small-cap company with a market capitalization of $1.11B. It ranks number 44 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.
For REPL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 35.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 27.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, REPL included.
Follow REPL freeREPL price chart and AI forecast
How REPL ranks among 5171 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Replimune Group, Inc. (REPL) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | REPL | Rank |
|---|---|---|
| Market Cap | $1.11B | 44/60 |
| P/B Ratio | 10.48x | 12/49 |
| EPS | $-3.15 | – |
| Book Value/Share | $1.12 | – |
| FCF/Share | $-2.98 | – |
Profitability & Margins
| Metric | REPL | Rank |
|---|---|---|
| ROE | -281.1% | 45/47 |
| ROA | -117.7% | 50/50 |
| ROIC | -139.1% | 53/53 |
| Tax Rate | 0.2% | – |
Financial Health
| Metric | REPL | Rank |
|---|---|---|
| Current Ratio | 5.23x | 30/59 |
| D/E Ratio | 1.39x | 10/53 |
| Financial Leverage | 2.39x | 10/52 |
| Interest Coverage | -26.4x | 21/37 |
| Working Capital | $162M | 51/59 |
Cash Flow
| Metric | REPL | Rank |
|---|---|---|
| Operating Cash Flow | -$279M | 45/57 |
| Free Cash Flow | -$281M | 38/50 |
| Capital Spending | -$1M | 16/50 |
Income Statement
| Metric | REPL | Rank |
|---|---|---|
| Operating Income | -$298M | 40/54 |
| Net Income | -$297M | 39/50 |
| R&D Expense | $213M | 27/56 |
Dividend & Shareholder Information
| Metric | REPL | Rank |
|---|---|---|
| Shares Outstanding | 94M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $201M | 79.5% of assets |
| Cash & Short-term Investments | $185M | 73.4% of assets |
| Total Liabilities | $147M | 58.2% of assets |
| Short-term Debt | $34M | 13.5% of assets |
REPL quarterly financials and insider trading
Replimune Group, Inc. (REPL) industry peers
Companies classified under the same SEC industry code as Replimune Group, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| REPL Replimune Group, Inc. | ▲ | $1.11B |
| AMGN Amgen Inc | ▼ | $233.82B |
| GILD Gilead Sciences, Inc. | ▲ | $193.67B |
| MRNA Moderna, Inc. | ▲ | $94.42B |
| ARGX Argenx Se | ▼ | $50.69B |
| RVMD Revolution Medicines, Inc. | ▲ | $40.57B |
| BIIB Biogen Inc. | ▼ | $34.13B |
| BNTX Biontech Se | ▲ | $22.18B |
| EXEL Exelixis, Inc. | ▶ | $15.42B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.92B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.83B |
| TECH Bio-Techne Corp | ▼ | $11.37B |
| RGEN Repligen Corp | ▶ | $10.39B |
| QGEN Qiagen N.V. | ▶ | $10.02B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.77B |
| IBRX Immunitybio, Inc. | ▲ | $9.73B |
| PCVX Vaxcyte, Inc. | ▲ | $9.71B |
| TWST Twist Bioscience Corp | ▲ | $9.06B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.99B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.17B |
| IMVT Immunovant, Inc. | ▲ | $5.52B |
| KOD Kodiak Sciences Inc. | ▲ | $5.39B |
| CGON Cg Oncology, Inc. | ▲ | $5.31B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.95B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.76B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $3.83B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.79B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.12B |
| DNLI Denali Therapeutics Inc. | ▼ | $2.81B |
| LIFE Atyr Pharma Inc | ▲ | $2.45B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.42B |
| ADMA Adma Biologics, Inc. | ▼ | $2.39B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.23B |
| NVAX Novavax Inc | ▲ | $2.11B |
| VCEL Vericel Corp | ▶ | $2.10B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $1.99B |
| MESO Mesoblast Ltd | ▶ | $1.79B |
| ALVO Alvotech | ▲ | $1.78B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.77B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.53B |
| IMCR Immunocore Holdings Plc | ▶ | $1.51B |
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.40B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.22B |
| VOR Vor Biopharma Inc. | ▲ | $1.14B |
| JATT Zura Bio Ltd | ▶ | $994M |
| MGTX Meiragtx Holdings Plc | ▶ | $950M |
| IMTX Immatics N.V. | ▲ | $902M |
| SLBT Sl Science Holding Ltd | ▶ | $884M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $844M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $832M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $831M |
| SANA Sana Biotechnology, Inc. | ▲ | $741M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $692M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $670M |
| PRME Prime Medicine, Inc. | ▲ | $655M |
| AURA Aura Biosciences, Inc. | ▲ | $633M |
| CADL Candel Therapeutics, Inc. | ▲ | $627M |
| SLDB Solid Biosciences Inc. | ▲ | $615M |
| DBVT Dbv Technologies S.A. | ▶ | $536M |
| VALN Valneva Se | ▼ | $505M |
Where REPL sits on the market map
Replimune Group, Inc. (REPL) stock news
Loading...
Replimune Group, Inc. (REPL) stock forecast FAQ
What is the Replimune Group, Inc. (REPL) stock forecast?
Our AI ranks Replimune Group, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Replimune Group, Inc. stock predictions?
For REPL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 35.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 27.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Replimune Group, Inc. forecasts updated?
Replimune Group, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Replimune Group, Inc.'s industry peers?
60 issuers in our coverage, REPL included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.